Liposomal bupivacaine in lower extremity arthroplasty: a comprehensive review
By
Fang, Yuang
Hu, Beilin
Mu, Guo
Yu, Hong
Zhou, Jun
April 6, 2026
Clinical Scorecard: A Thorough Examination of Liposomal Bupivacaine for Pain Management in Lower Limb Joint Replacement Surgery
At a Glance
Category Detail
Condition Key Mechanisms Liposomal bupivacaine provides sustained analgesia for up to 72 hours. [Source needed] Target Population Care Setting
Key Highlights
Liposomal bupivacaine reduces 24-hour opioid requirements by 35-50%. [Source needed] Decreases hospital length of stay by an average of 0.5 days. [Source needed] Enhances early-phase analgesia with a mean difference of -1.2 points on VAS at 24 hours. [Source needed] Particularly effective when used with adductor canal block in TKA procedures. [Source needed] Cost-effectiveness varies by surgical procedure. [Source needed] Guideline-Based Recommendations
Diagnosis
Management
Consider liposomal bupivacaine for postoperative pain management in lower limb joint replacement surgery. [Source needed] Monitoring & Follow-up
Risks
Patient & Prescribing Data
Liposomal bupivacaine provides significant opioid-sparing effects and enhances recovery. [Source needed]
Clinical Best Practices
Utilize liposomal bupivacaine in conjunction with regional anesthesia techniques. [Source needed] Assess cost-benefit profile of liposomal bupivacaine based on surgical procedure. [Source needed] Related Resources & Content
